Juan-Carlos Hernández-Boluda Selected Research

Imatinib Mesylate (Gleevec)

2/2012	Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
8/2011	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
8/2010	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
7/2010	XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
4/2009	Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.
10/2003	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juan-Carlos Hernández-Boluda Research Topics

Disease

8	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 11/2004
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2012 - 01/2002
4	Neoplasms (Cancer) 06/2022 - 05/2012
3	Venous Thrombosis (Deep-Vein Thrombosis) 11/2022 - 08/2010
3	Hemorrhage 11/2022 - 08/2010
3	Anemia 04/2017 - 11/2015
3	Thrombosis (Thrombus) 06/2015 - 08/2010
1	Infections 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2016
1	Rupture 11/2015
1	Leukemia 09/2014
1	Philadelphia Chromosome 09/2014
1	Polycythemia Vera 02/2012
1	Essential Thrombocythemia 08/2010
1	Genomic Instability 07/2010
1	Aplastic Anemia (Anemia, Hypoplastic) 04/2009
1	Neutropenia 10/2003
1	Exanthema (Rash) 02/2003
1	Muscle Cramp (Cramp) 02/2003

Drug/Important Bio-Agent (IBA)

6	Imatinib Mesylate (Gleevec)FDA Link 02/2012 - 10/2003
3	Proteins (Proteins, Gene)FDA Link 08/2011 - 07/2006
2	Erythropoietin FDA Link 04/2017 - 11/2004
2	Phosphotransferases (Kinase)IBA 09/2014 - 07/2010
1	CoagulantsIBA 11/2022
1	Immunomodulating AgentsIBA 11/2022
1	HematinicsIBA 04/2017
1	Prednisone (Sone)FDA LinkGeneric 01/2016
1	Danazol (Azol)FDA LinkGeneric 11/2015
1	Vitamin K FDA Link 06/2015
1	ponatinibIBA 09/2014
1	Tyrosine Kinase InhibitorsIBA 09/2014
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 06/2013
1	Codon (Codons)IBA 05/2012
1	Hydroxyurea (Hydrea)FDA LinkGeneric 02/2012
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2010
1	insulin receptor-related receptor (IRR)IBA 08/2010
1	SurvivinIBA 05/2005
1	InterferonsIBA 10/2003
1	EnzymesIBA 02/2003
1	Interferon-alpha (Interferon Alfa)IBA 01/2002
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2002

Therapy/Procedure

8	Therapeutics 04/2017 - 10/2003
4	Cell Transplantation 06/2022 - 12/2020
1	Transplantation 01/2022
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Secondary Prevention 06/2015
1	Stem Cell Transplantation 01/2002